208
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Cardiovascular effects of the addition of nilotinib to standard therapy for acute myeloid leukemia

ORCID Icon, , , ORCID Icon, ORCID Icon &
Pages 229-232 | Received 20 Dec 2016, Accepted 22 Apr 2017, Published online: 08 Jun 2017
 

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2017.1323268.

Additional information

Funding

Novartis Pharmaceuticals Corp. supported the research of Dr. Al Kali. Novartis Pharmaceuticals Corporation provided financial support for this work through their support of the DATA trial.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.